Loading...
Market
How will Quest Diagnostics' market share in Canadian diagnostic services change by end of 2025?
3
Resolution / Starting Odds
Increase by 5% or more • 33%
Fluctuate within ±5% • 33%
Decrease by 5% or more • 33%
Industry reports and market analysis
Story
Quest Diagnostics to Acquire LifeLabs for $985 Million (C$1.35 Billion)
Jul 3, 2024, 12:56 PM
Quest Diagnostics has announced its acquisition of LifeLabs, a Canadian provider of community laboratory tests, from OMERS for approximately $985 million, including debt. The deal, valued at C$1.35 billion, will enhance diagnostic services in Canada. The acquisition was officially announced on July 3, 2024. Quest Diagnostics trades under the ticker symbol $DGX.
View original story
Similar markets
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
PrecivityAD2™ dominates (>50%) • 25%
Sunbird Bio dominates (>50%) • 25%
Both share equally (~50% each) • 25%
Other diagnostic tests dominate • 25%
No change • 25%
Decrease by less than 10% • 25%
Decrease by 10-20% • 25%
Decrease by more than 20% • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Increase by more than 5% • 25%
Increase by 2-5% • 25%
Increase by less than 2% • 25%
No significant increase • 25%
UnitedHealth gains significant market share • 25%
Amedisys gains significant market share • 25%
Competitors gain significant market share • 25%
No significant change in market share • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Increased significantly • 25%
Increased slightly • 25%
No change • 25%
Decreased • 25%
New test leads market • 25%
Existing tests maintain dominance • 25%
Market share evenly distributed • 25%
Other outcome • 25%
Less than 20% • 25%
20-40% • 25%
41-60% • 25%
More than 60% • 25%
